Notice of Intent to Sole Source

Identification of the statutory authority permitting other than full and open competition: The acquisition is conducted under the authority of 41 United States Code (U.S.C.) 253 (c) (_1_) as set forth in Federal Acquisition Regulation (FAR) 6.302-_2_ Name of the proposed contractor(s): Merck Sharp & Dohme Corp. Nature of the acquisition and proposed unique qualifications of the contractor(s): This acquisition is to increase the target quantity for pediatric RecombivaxHB vaccine on the existing Merck pediatric contract in light of an ongoing supply constraint that has led to a critical national shortage of HEP B vaccine. Pediatric hepatitis B vaccines have experienced supply constraints since mid-2017. The supply gap for pediatric hepatitis B vaccine was anticipated to be resolved in the beginning of April 2018, but is now anticipated to continue through the end of 2018. To increase the HEP B vaccine target quantity as follows : Increase quantity of HEP B RecombivaxHB by 5,200,000 doses, for National Drug Codes (NDC): 00006-4981-00 SDV, 10-pack 00006-4093-02 SYR, 10-pack Any interested party may respond by Monday, May 14, 2018 at 12:00 PM EST to Christina McMillian via e-mail at wpn6@cdc.gov.